Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

Gene expression profile of cytokines in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with reduced conditioning.

Authors: Poloni, A  Sartini, D  Emanuelli, M  Trappolini, S  Mancini, S  Pozzi, V  Costantini, B  Serrani, F  Berardinelli, E  Renzi, E  Olivieri, A  Leoni, P 
Citation: Poloni A, etal., Cytokine. 2011 Mar;53(3):376-83. Epub 2011 Jan 5.
Pubmed: (View Article at PubMed) PMID:21211989
DOI: Full-text: DOI:10.1016/j.cyto.2010.12.008

There are no reliable markers useful to predict the onset or the evolution of chronic graft-versus-host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), although several candidate biomarkers have been identified from limited hypothesis-driven studies. In this study we evaluated 14 patients who received a reduced intensity conditioning HSCT. Seven patients had cGVHD, whereas 7 never developed cGVHD during the period of observation. The expression of 114 cytokines in immunoselected cell populations was explored by microarray analysis and 11 cytokines were selected for further evaluation by real-time PCR. Differential gene expression measurements showed a significant up-regulation for INFgamma (interferon, gamma) in CD8+ and for TNFSF3 (tumor necrosis factor superfamily, member 3) and for TNFSF10 (tumor necrosis factor superfamily, member 10) in CD14+ cell population when comparing cGVHD with control samples. The expression levels were significantly decreased for TNFSF10 in CD8+ cell population and for TNFSF12 (tumor necrosis factor superfamily, member 12) and for PDGFbeta (platelet-derived growth factor, beta) in CD4+. Our data seem to suggest that different immune populations can play a role in cGVHD pathogenesis and the early detection of gene expression profile in these patients could be useful in the monitoring of GVHD. We hypothesized that PDGFbeta down-regulation could represent a negative feedback to compensate for enhanced expression of its receptor recently reported.


Disease Annotations
Objects Annotated

Additional Information

CRRD Object Information
CRRD ID: 6482796
Created: 2012-05-03
Species: All species
Last Modified: 2012-05-03
Status: ACTIVE


RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.